Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients

Publisher： Karger

E-ISSN： 1421-9794|54|6|421-424

ISSN： 0009-3157

Source： Chemotherapy, Vol.54, Iss.6, 2008-09, pp. : 421-424

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-07 ,pp. : 79-84

Karger

Access to resources Recommend Favorite

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 4, 2015-04 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens

By Martinetti Antonia   Miceli Rosalba   Sottotetti Elisa   Di Bartolomeo Maria   de Braud Filippo   Gevorgyan Arpine   Dotti Katia Fiorella   Bajetta Emilio   Campiglio Manuela   Bianchi Francesca   Bregni Giacomo   Pietrantonio Filippo  

Cancers, Vol. 6, Iss. 3, 2014-08 ,pp. : 1753-1768

MDPI

Access to resources Recommend Favorite

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

By  

Chemotherapy, Vol. 62, Iss. 1, 2016-09 ,pp. : 80-84

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite